ADAM9 and prostate carcinoma: (2011) investigated the sensitivity of C4‐2 prostate cancer cells to a panel of chemotherapy drugs (doxorubicin, docetaxel, etoposide, cisplatin, and gemcitabine) upon ADAM9 silencing.